MEDIAN Technologies Vendor's profile
Managing mRECIST Criteria in Oncology Clinical Trials
Dienstag, 19. November 2013
mRECIST is now recommended by the European Association for the Study of the Liver(EASL) for clinical studies on advanced hepatocellular carcinoma (HCC) as it better fits disease evolution assessment than standard RECIST does.However, mRECIST for HCCis more complex than RECIST. Its management in c...
Contact MEDIAN Technologies
To feature here : Get in touch